Jefferies Financial Group Inc. Acquires New Stake in Zimmer Biomet Holdings, Inc. $ZBH

Jefferies Financial Group Inc. bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 32,768 shares of the medical equipment provider’s stock, valued at approximately $2,821,000.

Other institutional investors also recently modified their holdings of the company. DV Equities LLC bought a new stake in Zimmer Biomet in the 4th quarter valued at approximately $25,000. Tacita Capital Inc acquired a new stake in shares of Zimmer Biomet in the second quarter valued at approximately $26,000. Ancora Advisors LLC bought a new stake in shares of Zimmer Biomet in the second quarter worth $29,000. Monetary Solutions Ltd bought a new position in Zimmer Biomet in the fourth quarter valued at $30,000. Finally, Gen Wealth Partners Inc acquired a new stake in Zimmer Biomet in the 4th quarter valued at $31,000. 88.89% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on ZBH shares. Zacks Research upgraded shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research note on Tuesday. Sanford C. Bernstein upped their target price on Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a report on Thursday, August 6th. Citigroup decreased their price target on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a research note on Thursday, May 28th. Wall Street Zen lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings raised Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $104.42.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $101.10 on Friday. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. The business’s 50 day moving average price is $93.88 and its two-hundred day moving average price is $91.45. The company has a market cap of $19.28 billion, a PE ratio of 24.60, a price-to-earnings-growth ratio of 2.70 and a beta of 0.45. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $106.88.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. The company had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business’s revenue was up 4.8% on a year-over-year basis. During the same period last year, the firm posted $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.